Editas Get A Vetr Upgrade To Strong Buy
The Vetr crowd Monday upgraded their rating for Editas Medicine Inc (NASDAQ: EDIT), from 4 stars (Buy), issued 313 days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.
Editas has traded fairly sporadically over the course of March, which began with the stock entering a trough of over 18 percent to a low of $20.40.
The stock rallied back above $26 with a mid-month announcement the company was entering an R&D partnership with Allergan plc Ordinary Shares (NYSE: AGN), but fell back below $22.50 shortly after when it reported an offering of 4 million shares of common stock valued at $22.50.
Curretnly, the vetr crowd's average target price for Editas is up at $27.14, which is still below the average analyst target price of $33.50. Less than 2 percent of Vetr users are holding EDIT in their watch lists.
Latest Ratings for EDIT
|Mar 2017||Chardan Capital||Initiates Coverage On||Buy|
|Jun 2016||Jefferies||Initiates Coverage on||Hold|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.